Podcast

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

Author(s):

Drs Gushchin and Diaz-Montes discuss findings from the HOT trial evaluating health-related quality of life outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary ovarian cancer.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Vadim Gushchin, MD, and Teresa Diaz-Montes, MD, MPH, FACOG, about research they presented at the 2023 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. Dr Gushchin is the director of the hyperthermic intraperitoneal chemotherapy (HIPEC) program, as well as the leader of the Melanoma and Skin Cancer Center and director of Gastrointestinal Oncology in the Division of Surgical Oncology at Mercy Medical Center in Baltimore, Maryland. Dr Diaz-Montes is the associate director of The Lya Segall Ovarian Cancer Institute and the medical director of The Neil B. Rosenshein, MD, Institute for Gynecologic Care at Annapolis, as well as a gynecologic oncologist with The Gynecologic Oncology Center at Mercy Medical Center.

In our exclusive interview, Drs Gushchin and Diaz-Montes discussed findings from the phase 2 HOT trial (NCT02124421) evaluating health-related quality of life (QOL) outcomes after cytoreductive surgery and HIPEC in patients with primary ovarian cancer, the importance of devising more accurate strategies to assess patient QOL after receiving cytoreduction and HIPEC, and future directions for this research.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Laura J. Chambers, DO
Domenica Lorusso, MD, PhD
Domenica Lorusso, MD, PhD
Domenica Lorusso, MD, PhD
Laura J. Chambers, DO
Angeles A. Secord, MD, MHSc
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Kimberly Cannavale, MPH
Kimberly Cannavale, MPH
Amma Asare, MD, PhD